GCWM
ABBV icon

Graham Capital Wealth Management’s AbbVie ABBV Stock Holding History

Graham Capital Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-340
Closed -$542K – 42
2023
Q1 		$542K Buy
+340
New +$52K 0.08% 107
2022
Q1 		– Sell
-14,066
Closed -$1.9M – 107
2021
Q4 		$1.9M Buy
+14,066
New +$1.66M 1.55% 16

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Graham Capital Wealth Management's ABBV Position: Q2 2023 in Review

Graham Capital Wealth Management sold out of AbbVie (ABBV) in Q2 2023, closing a stake of 340 shares — an estimated $542K sold.

Graham Capital Wealth Management first reported a position in ABBV in Q4 2021 and held it in 2 quarters. The position peaked at $1.9M in Q4 2021. 3,076 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

  • Graham Capital Wealth Management reported no remaining AbbVie position as of Q2 2023 after selling out during the quarter.
  • Graham Capital Wealth Management sold 340 AbbVie shares in Q2 2023, an estimated $542K.
  • Graham Capital Wealth Management first reported a position in AbbVie in Q4 2021 and held it in 2 quarters.
  • Graham Capital Wealth Management's AbbVie position peaked at $1.9M in Q4 2021.
  • 3,076 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on Graham Capital Wealth Management's 13F filing for Q2 2023, filed 25 Jul 2023.